[Federal Register Volume 63, Number 214 (Thursday, November 5, 1998)] [Notices] [Pages 59793-59794] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-29567] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 98D-0298] Guidance for Industry on General/Specific Intended Use; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled ``Guidance for Industry on General/Specific Intended Use.'' FDA developed this guidance to satisfy a new section of the Federal Food, Drug, and Cosmetic Act (the act), which was added by the Food and Drug Administration Modernization Act of 1997 (FDAMA). This new section directs the agency to issue guidance explaining the general principles used by FDA in determining when a specific use may be added to a legally marketed device using premarket notification (510(k)) procedures and when a specific use triggers the need for a premarket approval (PMA) application. DATES: Written comments concerning this guidance may be submitted at any time. ADDRESSES: Submit written requests for single copies on a 3.5'' diskette of the guidance document to the Division of Small Manufacturers Assistance (HFZ-220), Center for Devices and Radiological, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two self-addressed adhesive labels to assist that office in processing your electronic or written request, or fax your request to 301-443-8818. Submit written comments on ``Guidance for Industry on General/Specific Intended Use'' to the contact person. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance entitled ``Guidance for Industry on General/ Specific Intended Use.'' FOR FURTHER INFORMATION CONTACT: Daniel G. Schultz, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-5072. SUPPLEMENTARY INFORMATION: I. Background Congress indicated that FDA should provide additional guidance on the approach that the agency takes when evaluating whether a new use, which appears to fall within the scope of the intended use of a legally marketed predicate device, is a new intended use that would require a PMA. This guidance is issued in accordance with the new section 513(i)(1)(F) of the act (21 U.S.C. 360c(i)(1)(f)), which was added by section 206 of FDAMA. The purpose of this document is to help medical device manufacturers understand the principles used by FDA to determine whether the addition of a specific indication for use to a medical device cleared for marketing with a general indication for use could trigger the need for a PMA application. The guidance is intended to help manufacturers answer the following questions: Under what circumstances is the device with a new, specific indication for use likely to be found to be substantially equivalent to a device legally marketed for a general indications for use? Conversely, when does a specific indication for use become a new intended use that requires submission of a PMA to establish the safety and effectiveness of the device? FDA announced the [[Page 59794]] availability of a draft guidance pertaining to General/Specific Intended use in the Federal Register of May 22, 1998 (63 FR 28392). The agency received two comments on the draft guidance. FDA has reviewed the comments and has made some revisions to the guidance in response to the comments. II. Significance of Guidance This guidance document represents the agency's current thinking on General/Specific Intended Use. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the applicable statute, regulations, or both. The agency has adopted Good Guidance Practices (GGP's), which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents (62 FR 8961, February 27, 1997). This guidance document is issued as a Level 1 guidance consistent with GGP's. III. Electronic Access In order to receive ``Guidance for Industry on General/Specific Intended Use'' via your fax machine, call the CDRH Facts-On-Demand (FOD) system at 800-899-0381 or 301-827-0111 from a touch-tone telephone. At the first voice prompt press 1 to access DSMA Facts, at second voice prompt press 2, and then enter the document number 499 followed by the pound sign (#). Then follow the remaining voice prompts to complete your request. Persons interested in obtaining a copy of the guidance may also do so using the World Wide Web (WWW). CDRH maintains an entry on the WWW for easy access to information including text, graphics, and files that may be downloaded to a personal computer with access to the WWW. Updated on a regular basis, the CDRH home page includes ``Guidance for Industry on General/Specific Intended Use,'' device safety alerts, Federal Register reprints, information on premarket submissions (including lists of approved applications and manufacturers' addresses), small manufacturers' assistance, information on video conferencing and electronic submissions, mammography matters, and other device-oriented information. The CDRH home page may be accessed at ``http://www.fda.gov/cdrh''. IV. Comments Interested persons may, at any time, submit written comments regarding this final guidance to the contact person. Such comments will be considered when determining whether to amend the current guidance. Dated: October 28, 1998. William B. Schultz, Deputy Commissioner for Policy. [FR Doc. 98-29567 Filed 11-4-98; 8:45 am] BILLING CODE 4160-01-F